Kidney function biomarkers
AssigneeMeso Scale Technologies, LLC.
InventorsEli N. Glezer, John Kenten, Sudeep Kumar, Galina Nikolenko
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of diagnosing a kidney disorder in a patient, as well as methods of monitoring the progression of a kidney disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or a therapeutic regimen. The invention also relates to assay methods used in connection with the diagnostic methods described herein.
Claims17
-26. (canceled)
A method of measuring biomarkers in a patient suspected of having a kidney disease or a causative condition thereof, the kidney disease or the causative condition thereof being selected from the group consisting of Lupus, HIV, AIDS, hepatitis B, hepatitis C, pyelonephritis, polycystic kidney disease, congenital defects, exposure to toxins, overuse of nonsteroidal anti-inflammatory drugs, acute renal failure, chronic kidney failure, hypertension, and diabetes, said method comprising:
- receiving a measurement of a level of a biomarker in a test sample obtained from the patient by contacting said test sample with capture antibodies to the biomarkers, wherein the biomarkers comprise FABP5, and one or more of TNF RI, CHGA, TNF RII, S100A4, E-Cadherin, TIMP1, and combinations thereof.
A method of detecting biomarkers in a patient suspected of having a kidney disease or a causative condition thereof, wherein the kidney disease or the causative condition thereof is selected from the group consisting of Lupus, HIV, AIDS, hepatitis B, hepatitis C, pyelonephritis, polycystic kidney disease, congenital defects, exposure to toxins, overuse of nonsteroidal anti-inflammatory drugs, acute renal failure, chronic kidney failure, hypertension, and diabetes, said method comprising:
- ordering a test comprising a measurement of levels of biomarkers in a test sample obtained from the patient by contacting said test sample with capture antibodies to the biomarkers, wherein the biomarkers comprise FABP5, and one or more of TNF RI, CHGA, TNF RII, S100A4, E-Cadherin, TIMP1, and combinations thereof.
A method of treating a patient for kidney disease or a causative condition thereof with at least one of an oral insulin, an ACE inhibitor, and an angiotensin II receptor blocker, wherein the kidney disease or the causative condition thereof is selected from the group consisting of chronic kidney failure, hypertension, and diabetes, comprising:
- (a) receiving a measurement of a level of a biomarker in a test sample obtained from the patient, wherein the biomarker comprises one or more of TNF RI, CHGA, TNF RII, S100A4, FABP5, E-Cadherin, TIMP1, and combinations thereof;
- (b) comparing said level to a normal control level of the biomarker;
- (c) evaluating from said comparing step (b) and selecting based on the evaluation whether said patient will be responsive to a treatment regimen;
- and
- (d) administering said treatment regimen based on said evaluating step (c), wherein said treatment regimen comprises administration of at least one of the oral insulin, the ACE inhibitor, and the angiotensin II receptor blocker.
A method of treating a patient for kidney disease or a causative condition thereof with at least one of an oral insulin, an ACE inhibitor, and an angiotensin II receptor blocker for, wherein the kidney disease or the causative condition thereof is selected from the group consisting of chronic kidney failure, hypertension, and diabetes, comprising:
- (a) evaluating a level of a biomarker in a test sample obtained from a patient prior to the commencement of treatment for the kidney disease or the causative condition thereof relative to a normal control level of the biomarker, wherein the biomarker comprises one or more of TNF RI, CHGA, TNF RII, S100A4, FABP5, E-Cadherin, TIMP1, and combinations thereof;
- and
- (b) administering said treatment regimen based on said evaluating step (a), wherein said treatment regimen comprises administration of at least one of an oral insulin, an ACE inhibitor, and an angiotensin II receptor blocker.
Dependencies are inferred from the claim text.